Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
Rhea-AI Summary
Palvella Therapeutics (Nasdaq: PVLA) received approval to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market, effective at the opening of trading on May 13, 2026.
The move reflects satisfaction of the Global Market’s higher listing standards. Shares will continue trading under the PVLA ticker, and no action is required from existing shareholders.
Positive
- Approval to transfer listing to the higher-tier Nasdaq Global Market
- Company has met Nasdaq Global Market financial, float, liquidity, and governance standards
- Ticker symbol PVLA and shareholder positions remain unchanged after uplisting
Negative
- None.
News Market Reaction – PVLA
In the May 13 session, PVLA declined 4.15%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings and financing | Positive | -13.0% | Q1 2026 results, major equity financing, strong cash and pipeline update. |
| May 04 | Clinical trial start | Positive | +0.6% | First patients dosed in Phase 2 LOTU trial of QTORIN rapamycin. |
| Apr 30 | Earnings call notice | Neutral | +4.8% | Announcement of timing and access details for Q1 2026 call. |
| Apr 20 | Clinical data presentations | Positive | -0.5% | Late-breaking Phase 3 SELVA and Phase 2 TOIVA QTORIN data for ISSVA. |
| Apr 13 | Board appointment | Positive | +1.5% | Addition of rare-skin-disease expert John D. Doux to Board. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been fundamentally positive, but price reactions have been mixed, with notable selloffs on strong clinical and financing updates.
Over the last month, Palvella has reported several key milestones. On Apr 7 and Apr 20, it highlighted highly statistically significant Phase 3 SELVA and positive Phase 2 TOIVA data for QTORIN™ 3.9% rapamycin gel and an updated corporate presentation. Management changes followed, with John Doux appointed to the Board on Apr 13. The company then announced Q1 2026 results and a major $230.0 million equity financing on May 7, and began dosing in the Phase 2 LOTU trial on May 4. Today’s uplisting news fits into this progression of corporate and clinical maturation.
Key Terms
nasdaq global market financial
nasdaq capital market financial
u.s. food and drug administration (fda) regulatory
public float financial
liquidity financial
corporate governance financial
u.s. securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Market.
“Palvella’s uplisting to the Nasdaq Global Market marks an important milestone in the Company’s continued progress,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics. “As we advance a pipeline of potential first-in-disease therapies, we believe this transition can further elevate Palvella’s visibility and support our mission to serve patients suffering from serious, rare skin diseases and vascular malformations.”
The transfer is effective at the opening of trading on Wednesday, May 13, 2026. The Company’s common stock will continue to trade under its existing ticker symbol, “PVLA.”
The Nasdaq Global Market has higher initial and continued listing standards than the Nasdaq Capital Market, including requirements related to financial metrics, public float, liquidity, and corporate governance. Palvella’s transfer to the Nasdaq Global Market follows its satisfaction of applicable listing requirements for the higher-tier market.
No action is required by existing shareholders in connection with the transfer. Palvella will continue to comply with all applicable Nasdaq listing standards and U.S. Securities and Exchange Commission reporting requirements.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com
